Patents by Inventor Daniela Kelm

Daniela Kelm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of tumors using specific anti-L1 antibody
    Patent number: 9260521
    Abstract: The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: February 16, 2016
    Assignees: MEDIGENE AG, DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFUNG DES OFFENTLICHEN RECHTS
    Inventors: Daniela Kelm, Peter Altevogt, Gerhard Moldenhauer, Frank Breitling, Achim Krueger, Silke Baerreiter, Sandra Luettgau, Ulrich Moebius, Yi Li, Susanne Sebens, Heiner Schaefer
  • TREATMENT OF TUMORS USING SPECIFIC ANTI-L1 ANTIBODY
    Publication number: 20140120117
    Abstract: The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.
    Type: Application
    Filed: October 3, 2013
    Publication date: May 1, 2014
    Applicants: MediGene AG, Deutsches Krebsforschungszentrum Stiftung des Oeffentlichen Rechts
    Inventors: Daniela Kelm, Peter Altevogt, Gerhard Moldenhauer, Frank Breitling, Achim Krueger, Silke Baerreiter, Sandra Luettgau, Ulrich Moebius, Yi Li, Susanne Sebens, Heiner Schaefer
  • Treatment of tumors using specific anti-L1 antibody
    Patent number: 8580258
    Abstract: The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.
    Type: Grant
    Filed: February 6, 2012
    Date of Patent: November 12, 2013
    Assignees: Deutsches krebsforschungszentrum Stiftung des Offentlichen Rechts, Medigene AG
    Inventors: Daniela Kelm, Peter Altevogt, Gerhard Moldenhauer, Frank Brietling, Achim Krueger, Silke Wolterink, Sandra Luettgau, Ulrich Moebius, Yi Li, Susanne Sebens, Heiner Schaefer
  • Treatment of tumors using specific anti-L1 antibody
    Patent number: 8138313
    Abstract: The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.
    Type: Grant
    Filed: June 13, 2008
    Date of Patent: March 20, 2012
    Assignees: Deutsches Krebsforschungszentrum Stiftung des offentlichen Rechts, MediGene AG
    Inventors: Daniela Kelm, Peter Altevogt, Gerhard Moldenhauer, Frank Brietling, Achim Krüger, Silke Bärreiter, Sandra Lüttgau, Ulrich Möbius, Yi Li
  • Inhibitors of L1 and ADAM10 for the treatment of carcinomas
    Patent number: 8003599
    Abstract: Described is a pharmaceutical composition comprising a compound(s) interfering with the biological activity of L1 and/or ADAM10 or their expression. Also described is the use of said compound(s) for the prevention/treatment of carcinomas like ovarian and endometrial carcinoma. Finally, the diagnosis of highly malignant forms of carcinomas which is based on the determination of the activity/expression of L1 and/or ADAM10 is described.
    Type: Grant
    Filed: July 27, 2005
    Date of Patent: August 23, 2011
    Assignee: Deutsches Krebsforschungszentrum
    Inventors: Peter Altevogt, Daniela Kelm, Mina Fogel